|
PSCI-17-072 |
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue |
|
PSCI-17-081 |
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
|
PSCI-18-004 |
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients |
|
PSCI-18-016 |
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones |
|
PSCI-18-022 |
Molecular Genetic, Host-Derived and Clinical Determinants of Long-Term Survival in Glioblastoma |
|
PSCI-18-071 |
A biospecimen collection study to evaluate the pharmacokinetic,pharmacodynamic, and resistance profile to trametinib and dabrafenib in BRAF-V600E mutated recurrent gliomas |
|
PSCI-18-078 |
CUFF Study: Characterization of Upper Limb Function following Mastectomy and Reconstruction for Breast Cancer |
|
PSCI-18-091 |
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) |
|
PSCI-18-092 |
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) |
|
PSCI-18-109 |
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors |
